Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Jun 27, 2013; 5(6): 323-327
Published online Jun 27, 2013. doi: 10.4254/wjh.v5.i6.323
Published online Jun 27, 2013. doi: 10.4254/wjh.v5.i6.323
Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus
Dimitrios Dimitroulis, Eleftherios Spartalis, Emmanuel Pikoulis, Gregory Kouraklis, Second Department of Propedeutic Surgery, Athens University Medical School, “Laiko” Hospital, 11527 Athens, Greece
Serena Valsami, Blood Transfusion Department, Athens University Medical School, Areteion Hospital, 11527 Athens, Greece
Author contributions: Dimitroulis D and Kouraklis G designed the research; Valsami S performed the research; Spartalis E and Pikoulis E analyzed the data; Dimitroulis D and Spartalis E wrote the paper.
Correspondence to: Eleftherios Spartalis, MD, MSc, Second Department of Propedeutic Surgery, Athens University Medical School, “Laiko” Hospital, Vasilissis Sofias 49, 11527 Athens, Greece. eleftherios.spartalis@gmail.com
Telephone: +30-697-4714078 Fax: +30-210-7456972
Received: February 27, 2013
Revised: April 17, 2013
Accepted: May 8, 2013
Published online: June 27, 2013
Revised: April 17, 2013
Accepted: May 8, 2013
Published online: June 27, 2013
Core Tip
Core tip: Hepatitis C virus and human immunodeficiency virus co-infected patients with Hepatocellular carcinoma, undergo the same therapeutic protocol as their mono-infected counterparts, but special issues such as interaction between regimens, withdrawal of therapy and choice of immunosuppressive agents, demand a careful approach by specialists.